Gastrointestinal Cancers

The Food and Drug Administration (FDA) has granted a priority review to a supplemental new drug application for Lonsurf (TAS-102; trifluridine/tipiracil) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

While having a career as a flight attendant allows individuals to travel the globe, exposure to carcinogens and frequent disruptions in circadian rhythms may increase cancer prevalence in these individuals, according to recent research published in the journal Environmental Health.

But just what information is most useful to patients with NETs, and where are the gaps in the educational and supportive resources to which they have access? A study – presented at the Gastrointestinal Cancers Symposium on Jan. 19, in San Francisco – explored just that.

Keytruda (pembrolizumab) was granted FDA approval for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more lines of chemotherapy and are PD-L1-positive.

Patients with advanced gastric cancer tend to use their health care resources more often and have a worse quality of life than those without the disease

Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.

Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have undergone at least two courses of chemotherapy.

Dr. Daniel H. Ahn, D.O., spoke with CURE about new advances in gastroesophageal cancers including immunotherapies and stemness inhibitors.

Surgical palliation improved quality of live and solid food intake in patients with certain types of gastric cancer, according to a recent study.

A recent study found that Opdivo improves survival in patients with gastric or gastroesophageal junction (GEJ) cancer.

The JAVELIN trial showed that many patients with gastric cancer could benefit from immunotherapy.

Since chemotherapy can offer only a limited amount of help in fighting gastroesophageal cancers, a growing emphasis on prevention — as well as on the development of immunotherapies — will be extremely important.

For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.

In the oncology world, gastrointestinal cancers may be the next in line to realize the promise of immunotherapy.

Diagnoses in younger people and two causative infections are providing clues about how to better prevent and treat gastric cancer.

The decision to remove one's stomach may be difficult, but it can also be life-saving.

Results from new clinical trials signal a role for the immunotherapy Opdivo in the treatment of gastric cancer and heavily pretreated esophageal cancer.

I will be out on the street in New York City on November 1 to cheer on James Blake.

Moving back into the light.

The medical team had reached some conclusions.

This is how I became hospital property.

Twenty strokes signaled that there was trouble, though no one would have suspected a tumor.

It is now well recognized that the presence of a molecular abnormality shown to be actionable in one tumor type may be highly clinically relevant in other malignancies.

In the hopes of recreating the successes achieved in other solid malignancies, researchers have evaluated many types of targeted therapy for the treatment of advanced gastric cancer.

Debbie Zelman is the founder and president of Debbie's Dream Foundation: Curing Stomach Cancer, a nonprofit organization that is dedicated to educating and supporting patients and their families.

Among patients with metastatic gastric cancer treated with the PD-1 inhibitor Keytruda, the agent showed promising activity, according to updated findings from the KEYNOTE-012 study presented at the Gastrointestinal Cancers Symposium.

Why is November not named an "awareness month?" Because stomach cancer isn't only about awareness.

The FDA approves Cyramza (ramucirumab) in combination with paclitaxel for the treatment of advanced gastric cancer or GEJ adenocarcinoma.